TY - JOUR
TI - Expression of oncofetal RNA-binding protein CRD-BP/IMP1 predicts clinical outcome in colon cancer
AU - Dimitriadis, E.
AU - Trangas, T.
AU - Milatos, S.
AU - Foukas, P.G.
AU - Gioulbasanis, I.
AU - Courtis, N.
AU - Nielsen, F.C.
AU - Pandis, N.
AU - Dafni, U.
AU - Bardi, G.
AU - Ioannidis, P.
JO - International Journal  of Cancer
PY - 2007
VL - 121
TODO - 3
SP - 486-494
PB - 
SN - 0020-7136
TODO - 10.1002/ijc.22716
TODO - messenger RNA;  oncofetal antigen;  protein crd bp;  protein imp1;  RNA binding protein;  unclassified drug, adult;  aged;  article;  cancer recurrence;  cancer survival;  colon cancer;  correlation analysis;  female;  human;  human tissue;  immunohistochemistry;  intestine crypt;  major clinical study;  male;  metastasis;  outcome assessment;  prediction;  priority journal;  protein expression;  protein localization;  reverse transcription polymerase chain reaction;  tissue distribution, Adult;  Aged;  Aged, 80 and over;  Colonic Neoplasms;  Female;  Gene Expression;  Humans;  Immunohistochemistry;  Intestinal Mucosa;  Male;  Middle Aged;  Prognosis;  Reverse Transcriptase Polymerase Chain Reaction;  RNA, Messenger;  RNA-Binding Proteins
TODO - The oncofetal CRD-BP/IMP1 RNA binding protein regulates post-transcriptionally a handful of RNA transcripts, implicated in cell adhesion and invadopodia formation and was recently identified as a target of the β-catenin/Tcf transcription factor that is constitutively activated in colorectal carcinomas (CRCs). The expression of CRD-BP/IMP1 was studied in normal adult intestines and CRCs. In normal mucosa, CRD-BP/IMP1 immunoreactivity was observed in few scattered cells located predominantly at or near the bottom of the crypts, whereas in CRCs the protein was detectable in tumor cells of 50% of the specimens analyzed. CRD-BP/ IMP1 mRNA expression was measured by qRT-PCR in 78 CRCs. Thirty-two (41%) of the specimens were negative or had negligible expression, whereas the remaining forty-six (59%) expressed a wide range of CRD-BP/IMP1 mRNA levels. CRD-BP/IMP1 mRNA expression correlated with that of the putative stem/progenitor cell marker Musashi-1 mRNA (p = 0. 035). CRD-BP/IMP1 positive tumors metastasized and/or recurred more frequently (p = 0.001) and its expression defined a group of patients with shorter survival (p = 0.014). Furthermore, in a multivariate analysis CRD-BP/IMP1 expression was found to be an independent predictor of survival (p = 0.015). For stage I & II patients, the differences in metastasis/recurrence and survival rates remained significant (p = 0.001 and 0.033, respectively). These findings indicate that CRD-BP/IMP1 positive tumors exhibit early disease dissemination and unfavorable prognosis. © 2007 Wiley-Liss, Inc.
ER -